Jason Luke

Mar 1, 2024 | jitc.bmj.com | Dirk Schadendorf |Jason Luke |Paolo A Ascierto |Georgina V. Long

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Aug 18, 2023 | onclive.com | Jason Luke

Aug 18, 2023Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.

Jul 6, 2023 | fal.cn | Xiaoran Zhang |Laura J. Ferris |Mark B. Faries |Jason Luke

The Case for Continuous Use of SLNBThe value of pathologically staged regional lymph nodes should not be underestimated. The MSS of stage IIB/C patients who might consider the newly approved adjuvant regimens should not be compared with that of stage IIIA patients as a SLN metastasis would upstage them to either stage IIIC or IIID.

Jun 6, 2023 | onclive.com | Jason Luke

Jason Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, director, Cancer Immunotherapeutic Center, Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, discusses the final analysis of distant metastasis–free survival (DMFS) in the phase 3 KEYNOTE-716 trial (NCT03553836) of pembrolizumab (Keytruda) vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma.

Apr 20, 2023 | onclive.com | Jason Luke

Jason Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, director, Cancer Immunotherapeutic Center, Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, discusses initial results from the phase 1 GLIMMER-01 trial (NCT05259696) of E-602 in advanced solid tumors. E-602 is a first-in-class fusion protein consisting of an engineered human sialidase (Neu2) and a human IgG1 Fc region.